Incorporating newer agents in the treatment of acute myeloid leukemia

Raj, Renju V.; Abedin, Sameem; Atallah, Ehab

doi:10.1016/j.leukres.2018.10.008

Cited by 9 publications

(9 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tables 1 and 2 provide the overall age-standardized mortality rates per 100 000 men and women, respectively, and the number of deaths from selected cancers registered in 2015 in 36 European countries and the EU-28 as a whole. Supplementary Figures S1-S8, available at Annals of Oncology online, show rates (from largest to smallest) for the EU-28 by cancer site (supplementary figure S1, available at Annals of Oncology online), and for all neoplasms (supplementary figure S2, available at Annals of Oncology online) and selected major cancers (supplementary figures S3-S8, available at Annals of Oncology online) by country (supplementary material, available at Annals of Oncology online).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Cancer mortality in Europe in 2015 and an overview of trends since 1990

et al. 2019

View full text Add to dashboard Cite

Background: Cancer mortality in Europe has been decreasing since the late 1980s or 1990s in some countries with different patterns in many areas. In this study, we updated trends in cancer mortality in Europe. Materials and methods:We extracted data from the World Health Organization mortality database for 24 cancer sites, 36 European countries and the European Union (EU) as a whole over the 1990-2017 period. We computed age-standardized death rates per 100 000 person-years, and we carried out a joinpoint regression analysis of mortality trends from all cancers and selected major neoplasms. The estimated annual percent change (APC) for each identified linear segment, and the weighted average APC (AAPC) over the entire study period were provided as summary measures of the changes in rates over the time period.Results: In 2015, the age-standardized mortality rates from all cancers in the EU were 137.5 deaths per 100 000 in men and 85.7 in women. Eastern European countries showed the highest rates with values over 150 deaths per 100 000 in men and over 100 deaths per 100 000 in women. Mortality from all cancers in the EU declined annually by 1.5% in men since 2006 and by 0.8% in women since 2007. Most cancer sites showed decreasing trends, with steady declines over the whole period for cancers of stomach, intestines, lung in men, breast and prostate. Unfavourable mortality trends persisted for cancers of liver, lung in women, pancreas, besides skin and kidney in men. Conclusions:The downward trends in total cancer mortality in Europe still continue over the last decade. However, the trends were less favourable in most eastern European countries. Tobacco control in men (but not in women), improvements in diagnosis and therapy were the main underlying factors of these trends.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Subsequent advancements in therapies were the key underlying factors of the downward trend in mortality from leukaemias, targeted therapy has improved the prognosis of patients with chronic myelogenous leukemia and allogeneic hematopoietic cell transplantation improved survival in all malignant hematologic diseases [33][34][35][36].…”

Section: Discussionmentioning

confidence: 99%

Cancer mortality in Europe in 2015 and an overview of trends since 1990

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Since 2017 several new agents have expanded the treatment arsenal for patients with AML, these include targeted as well as non-targeted therapies. The US Food and Drug Administration (FDA) has approved glasdegib, venetoclax, ivosidenib, midostaurin, enasidenib, gilteritinib, CPX-351, and gemtuzumab ozogamicin (GO), the European Medicines Agency (EMA) has done likewise for midostaurin, CPX-351, and GO [22][23][24][25][26].…”

Section: Overview Of the Marketmentioning

confidence: 99%

Evaluating ivosidenib for the treatment of acute myeloid leukemia

Donker

Ossenkoppele

2020

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Introduction: Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults, but the results for patients with AML are still unsatisfactory. The discovery of new mutations in AML, including IDH mutations, has opened the door for treatment with targeted agents. Ivosidenib is a selective, potent inhibitor of the IDH1 mutant protein.Areas covered: This review summarizes the mechanism of action, safety profile and efficacy of ivosidenib for patients with IDH1-mutated AML. The authors then provide their expert perspectives on the use of the drug including their future perspectives. Expert opinion: Ivosidenib is a promising, most probably practice changing, new drug for the treatment of IDH1-mutated AML. Current phase III trials are ongoing to evaluate the addition of ivosidenib to the current standards-of-care. In the near future, more drug combinations are awaited. Challenges for the future include the development of resistance and establishing the duration of maintenance therapy.

show abstract

“…Subsequent trials (ALFA-0701 phase III study, AML-19 phase III study, MyloFrance 1 and 2 studies) were conducted with lower doses of GO (3 mg/m 2 on days 1, 4, and 7, and 6 mg/m 2 on day 1 and 3 mg/m 2 on day 4) in patients with de novo AML. After a long break, GO was reapproved by the FDA in 2017 for treating CD33-positive newly diagnosed or RR-AML, with a black-book warning for hepatotoxicity and veno-occlusive disease 66,67. A subtype of AML known as core binding factor (CBF) AML responds well to GO 68.…”

Section: Second-generation Flt3 Tyrosine-kinase Inhibitorsmentioning

confidence: 99%

<p>A personalized approach to acute myeloid leukemia therapy: current options</p>

Illangeswaran¹,

Das²,

Paul³

et al. 2019

PGPM

View full text Add to dashboard Cite

Therapeutic options for acute myeloid leukemia (AML) have remained unchanged for nearly the past 5 decades, with cytarabine and anthracyclines and use of hypomethylating agents for less intensive therapy. Implementation of large-scale genomic studies in the past decade has unraveled the genetic landscape and molecular etiology of AML. The approval of several novel drugs for targeted therapy, including midostaurin, enasidenib, ivosidenib, gemtuzumab–ozogamicin, and CPX351 by the US Food and Drug Administration has widened the treatment options for clinicians treating AML. This review focuses on some of these novel therapies and other promising agents under development, along with key clinical trial findings in AML.

show abstract

Incorporating newer agents in the treatment of acute myeloid leukemia

Cited by 9 publications

References 45 publications

Cancer mortality in Europe in 2015 and an overview of trends since 1990

Cancer mortality in Europe in 2015 and an overview of trends since 1990

Evaluating ivosidenib for the treatment of acute myeloid leukemia

<p>A personalized approach to acute myeloid leukemia therapy: current options</p>

Contact Info

Product

Resources

About